Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Mersana Therapeutics stock

Learn how to easily invest in Mersana Therapeutics stock.

Mersana Therapeutics is a biotechnology business based in the US. Mersana Therapeutics shares (MRSN) are listed on the NASDAQ and all prices are listed in US Dollars. Mersana Therapeutics employs 169 staff and has a trailing 12-month revenue of around $11.9 million.

How to buy Mersana Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – MRSN. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Mersana Therapeutics stock price (NASDAQ: MRSN)

Use our graph to track the performance of MRSN stocks over time.

Mersana Therapeutics shares at a glance

Information last updated 2023-01-25.
Latest market close$6.56
52-week range$2.68 - $8.34
50-day moving average $6.31
200-day moving average $5.73
Wall St. target price$16.83
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.49

Buy Mersana Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Mersana Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mersana Therapeutics price performance over time

Historical closes compared with the close of $6.56 from 2023-01-25

1 week (2023-01-20) 2.50%
1 month (2022-12-27) 14.89%
3 months (2022-10-27) -6.02%
6 months (2022-07-27) 15.90%
1 year (2022-01-27) 52.56%
2 years (2021-01-27) -64.48%
3 years (2020-01-27) 7.62
5 years (2018-01-26) 16.34

Mersana Therapeutics financials

Revenue TTM $11.9 million
Gross profit TTM $-131,970,000
Return on assets TTM -48.36%
Return on equity TTM -169.48%
Profit margin 0%
Book value $0.92
Market capitalisation $654.5 million

TTM: trailing 12 months

Mersana Therapeutics share dividends

We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.

Mersana Therapeutics share price volatility

Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $2.68 up to $8.338. A popular way to gauge a stock's volatility is its "beta".

MRSN.US volatility(beta: 1.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 1.7175. This would suggest that Mersana Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Mersana Therapeutics overview

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc.

Frequently asked questions

What percentage of Mersana Therapeutics is owned by insiders or institutions?
Currently 1.141% of Mersana Therapeutics shares are held by insiders and 97.033% by institutions.
How many people work for Mersana Therapeutics?
Latest data suggests 169 work at Mersana Therapeutics.
When does the fiscal year end for Mersana Therapeutics?
Mersana Therapeutics's fiscal year ends in December.
Where is Mersana Therapeutics based?
Mersana Therapeutics's address is: 840 Memorial Drive, Cambridge, MA, United States, 02139
What is Mersana Therapeutics's ISIN number?
Mersana Therapeutics's international securities identification number is: US59045L1061
What is Mersana Therapeutics's CUSIP number?
Mersana Therapeutics's Committee on Uniform Securities Identification Procedures number is: 59045L106

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site